4.1 Article

Solid Organ Transplantation in HIV plus Recipients: Italian Experience

Journal

TRANSPLANTATION PROCEEDINGS
Volume 48, Issue 2, Pages 424-430

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2015.12.049

Keywords

-

Ask authors/readers for more resources

Introduction. According to current estimates, there are about 540,000 patients who are infected with HIV in Western Europe, of which about 3100 are potential candidates for organ transplantation. In Italy, there are currently 85 HIV patients on the transplant list. Methods. Organ transplantation activity in HIV recipients from 2002 to December 2014 was assessed from the database provided by the Transplant Center of Modena until the year 2011. For the years 2012 to 2014, data are from the Transplant Information System (SIT). The follow-up data have been extracted from the function Quality of the SIT. Results. The transplant centers on Italian territory that meet the requirements according to national protocol are in total 29: 11 for the liver, 9 for the kidney including 1 pediatric, 3 for the heart, 3 for the lungs, and for 3 for the combined kidney-pancreas. Since 2002, 257 organ transplantations were carried out, including 185 liver, 59 kidney, 5 combined liver-kidney, 5 combined kidney-pancreas, 2 heart, and 1 double lung. The first cause of death is represented by co-hepatitis C virus infection, in particular in 26 liver recipients (37%) and in 3 kidney recipients (20%). Conclusions. The analysis showed that transplantation activity in HIV is on the rise, especially in the last 2 years, with an outcome similar to that reported in the literature.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Surgery

Organ donor screening for carbapenem-resistant gram-negative bacteria in Italian intensive care units: the DRIn study

Francesco Procaccio, Lucia Masiero, Francesca Vespasiano, Paolo A. Grossi, Carlo Gagliotti, Annalisa Pantosti, Mario Caprio, Letizia Lombardini, Alessandro Nanni Costa, Daniela Maccarone, Bruno Giacon, Angelo Saracino, Pellegrino Mancini, Paolo Giannattasio, Gabriela Sangiorgi, Maurizia Licari, Maurizio Valeri, Montserrat Munoz Lopez, Massimo Moschini, Raffaella Giacometti, Annarita Panebianco, Roberto Littera, Angelita Butera, Manuela Bonizzoli, Laura Pilati, Atanassios Dovas, Fabio Lazzarini, Elena Coluccio, Sergio Vesconi, Angelo Ghirardini, Francesca Puoti, Andrea Ricci, Paola Di Ciaccio

AMERICAN JOURNAL OF TRANSPLANTATION (2020)

Article Surgery

Association of immigration background with kidney graft function in a publicly funded health system: a nationwide retrospective cohort study in Italy

Alessandra Agnese Grossi, Umberto Maggiore, Francesca Puoti, Paolo Antonio Grossi, Mario Picozzi, Massimo Cardillo

TRANSPLANT INTERNATIONAL (2020)

Article Surgery

Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study

Silvia Trapani, Lucia Masiero, Francesca Puoti, Maria C. Rota, Martina Del Manso, Letizia Lombardini, Flavia Riccardo, Antonio Amoroso, Patrizio Pezzotti, Paolo A. Grossi, Silvio Brusaferro, Massimo Cardillo

Summary: Italy has set up a dedicated surveillance system for COVID-19 cases, revealing higher infection and mortality rates in solid organ transplant recipients, especially in the Lombardy region. Heart transplant recipients have a higher infection rate, while liver transplant recipients have a lower rate. Further studies on disease management and evolution are needed for these high-risk patients.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Article Surgery

Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor

Tommaso Maria Manzia, Carlo Gazia, Ilaria Lenci, Roberta Angelico, Luca Toti, Andrea Monaco, Alessandro Anselmo, Leonardo Baiocchi, Paolo Grossi, Giuseppe Tisone

Summary: This case report describes the first successful liver transplantation using a liver procured from a SARS-CoV-2 positive donor, with the recipient clearing the infection and recovering normal liver function after the surgery. The findings suggest that the prompt use of SARS-CoV-2 infected liver donors could offer a life-saving opportunity for SARS-CoV-2 positive patients who have developed neutralizing antibodies.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Review Infectious Diseases

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

Massimo Andreoni, Matteo Bassetti, Salvatore Corrao, Francesco Giuseppe De Rosa, Vincenzo Esposito, Marco Falcone, Paolo Grossi, Federico Pea, Nicola Petrosillo, Carlo Tascini, Mario Venditti, Pierluigi Viale

Summary: Dalbavancin is a novel antibiotic with long-lasting effects for treating Gram-positive infections. Research indicates its potential value in other indications such as osteomyelitis, prosthetic joint infections, and infective endocarditis.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Article Microbiology

Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome

Monica Miele, Alessia Gallo, Mariangela Di Bella, Francesca Timoneri, Floriana Barbera, Marco Sciveres, Silvia Riva, Paolo Grossi, Pier Giulio Conaldi

Summary: In a liver-transplanted recipient with refractory recurrent CMV infection, the infusion of allogenic CMV-reactive T-cells from a healthy CMV-seropositive donor resulted in the clearance of CMV infection and resolution of the pathological manifestations. The study suggests that infusion of allogenic CMV-reactive T-cells can be an effective strategy to treat CMV infection recurrence when autologous virus specific T cell clones cannot be generated.

MICROORGANISMS (2021)

Article Surgery

Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?

Renato Romagnoli, Salvatore Gruttadauria, Giuseppe Tisone, Giuseppe Maria Ettorre, Luciano De Carlis, Silvia Martini, Francesco Tandoi, Silvia Trapani, Margherita Saracco, Angelo Luca, Tommaso Maria Manzia, Ubaldo Visco Comandini, Riccardo De Carlis, Valeria Ghisetti, Rossana Cavallo, Massimo Cardillo, Paolo Antonio Grossi

Summary: In specific circumstances, liver transplant from donors with active COVID-19 may be considered for recipients with SARS-CoV-2 immunity to safely expand the donor pool and minimize transmission risks.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Article Infectious Diseases

Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

Alessandra Mularoni, Maria Lina Mezzatesta, Michele Pilato, Alice Annalisa Medaglia, Adriana Cervo, Dafne Bongiorno, Ausilia Aprile, Angelo Luca, Stefania Stefani, Paolo Grossi

Summary: A challenging case of metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis was successfully treated with surgical debridement and antibiotic therapy. Time-kill curves demonstrated strong synergistic effect of the triple antibiotic combination of ceftazidime/avibactam, aztreonam, and amikacin.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Article Immunology

Liver transplantation from active COVID-19 donors: Is it ethically justifiable?

Alessandra Agnese Grossi, Federico Nicoli, Massimo Cardillo, Salvatore Gruttadauria, Giuseppe Tisone, Giuseppe Maria Ettorre, Luciano De Carlis, Renato Romagnoli, Carlo Petrini, Paolo Antonio Grossi, Mario Picozzi

Summary: The ethical analysis of performing liver transplantation in patients with resolved or active COVID-19 shows that the decision is ethically justifiable. By considering medical indications, patient preferences, quality of life, and contextual features, the decision is made on a case-by-case basis. Shared decision-making allows for the integration of clinical options with the patient's subjective preferences and considerations, providing valid informed consent tailored to individual circumstances. Including carefully selected SARS-CoV-2 positive donors offers the opportunity to save lives for patients who may have limited chances of receiving a transplant.

TRANSPLANT INFECTIOUS DISEASE (2022)

Review Health Care Sciences & Services

Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice

Federica Invernizzi, Marta Cilla, Silvia Trapani, Maria Guarino, Valentina Cossiga, Martina Gambato, Maria Cristina Morelli, Filomena Morisco, Patrizia Burra, Annarosa Floreani

Summary: Autoimmune liver diseases (AILDs) include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. The etiology of AILD is not well understood but is believed to involve a combination of genetic and environmental factors. AILDs commonly affect young individuals and have a highly variable clinical course. They significantly impact quality of life and can progress to liver decompensation, hepatocellular or cholangiocarcinoma, and end-stage liver disease requiring transplantation. This review highlights the importance of considering sex characteristics and conducting sex-specific analysis in future studies for better understanding and treatment development of AILD.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Gastroenterology & Hepatology

COVID-19 positive donor for solid organ transplantation

Maddalena Peghin, Paolo Antonio Grossi

Summary: The COVID-19 pandemic has had a significant impact on organ donation and transplantation globally. Based on current experience, transplantation of non-lung organs from deceased donors with active SARS-CoV-2 infection has been considered possible and safe. With the evolving outbreak and the availability of vaccines and treatments, organs from deceased donors with active SARS-CoV-2 infection may be considered for transplantation in recipients with limited opportunities and specific immunity. Expert opinions are provided in the absence of definitive data and standardized acceptance patterns.

JOURNAL OF HEPATOLOGY (2022)

Review Immunology

SARS-CoV-2 Vaccination in Solid-Organ Transplant Recipients

Maddalena Peghin, Elena Graziano, Paolo Antonio Grossi

Summary: The COVID-19 pandemic presents significant challenges for solid organ transplant recipients, and although vaccines reduce the risk of COVID-19, they have lower immunogenicity and efficacy in waitlisted candidates and SOT recipients. Vaccination priority is recommended for SOT patients and their family members, along with adherence to preventive measures.

VACCINES (2022)

Review Microbiology

Phaeohyphomycosis in Solid Organ Transplant Recipients: A Case Series and Narrative Review of the Literature

Davide Lo Porto, Andrea Cona, Francesca Todaro, Elena De Carolis, Francesca Cardinale, Neha Hafeez, Giuseppina Di Martino, Pier Giulio Conaldi, Maurizio Sanguinetti, Paolo Antonio Grossi, Alessandra Mularoni

Summary: Phaeohyphomycosis is a diverse infection caused by pigmented fungi, and solid organ transplant recipients are at increased risk due to immunosuppression. In this study, three successful cases of phaeohyphomycosis in transplant recipients were treated with surgery and antifungal therapy. A literature review revealed a wide range of fungal species, with Alternaria being the most common. Early diagnosis and treatment are crucial in preventing disease dissemination.

JOURNAL OF FUNGI (2023)

Article Immunology

Favorable experience of transplant strategy including liver grafts from COVID-19 donors: One-year follow-up results

Silvia Martini, Margherita Saracco, Donatella Cocchis, Fabrizia Pittaluga, Bruna Lavezzo, Francesca Barisone, Luigi Chiusa, Antonio Amoroso, Massimo Cardillo, Paolo A. Grossi, Renato Romagnoli

Summary: This study evaluated the medium-term outcomes of liver transplant recipients from COVID-19 donors and found favorable results in terms of patient survival. However, there was a higher risk of hepatic artery thrombosis compared to recipients from COVID-19-negative donors.

TRANSPLANT INFECTIOUS DISEASE (2023)

No Data Available